IMMUNOVANT, INC. (IMVT) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 117.10M USD | Liabilities, Current |
| Cash and equivalents | 797.80M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 697.00K USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $117.10M | $797.80M | (m) | $697.00K | (m) | (m) |
| 2026-03-31 | (m) | $104.42M | $902.11M | (m) | $1.13M | (m) | (m) |
| 2025-12-31 | (m) | $66.26M | $994.52M | (m) | $1.64M | (m) | (m) |
| 2025-09-30 | (m) | $63.25M | $521.87M | (m) | $1.97M | (m) | (m) |
| 2025-06-30 | (m) | $52.90M | $598.91M | (m) | $1.94M | (m) | (m) |
| 2025-03-31 | (m) | $68.78M | $713.97M | (m) | $2.08M | (m) | (m) |
| 2024-12-31 | (m) | $68.31M | $374.69M | (m) | $2.22M | (m) | (m) |
| 2024-09-30 | (m) | $66.65M | $472.94M | (m) | $1.88M | (m) | (m) |
| 2024-06-30 | (m) | $45.02M | $560.00M | (m) | $2.42M | (m) | (m) |
| 2024-03-31 | (m) | $48.61M | $635.37M | (m) | $5.34M | (m) | (m) |
| 2023-12-31 | (m) | $32.10M | $690.94M | (m) | $1.03M | (m) | (m) |
| 2023-09-30 | (m) | $40.26M | $269.93M | (m) | $1.42M | (m) | (m) |
| 2023-06-30 | (m) | $51.36M | $329.96M | (m) | $823.00K | (m) | (m) |
| 2023-03-31 | (m) | $43.30M | $376.53M | (m) | $700.00K | (m) | (m) |
| 2022-12-31 | (m) | $41.26M | $432.61M | (m) | $704.00K | (m) | (m) |
| 2022-09-30 | (m) | $31.78M | $405.77M | (m) | $3.78M | (m) | (m) |
| 2022-06-30 | (m) | $21.24M | $427.20M | (m) | $13.18M | (m) | (m) |
| 2022-03-31 | (m) | $44.52M | $493.82M | (m) | $12.23M | (m) | (m) |
| 2021-12-31 | (m) | $36.35M | $527.00M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $28.38M | $558.95M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $20.52M | $379.00M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $18.77M | $400.15M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $16.48M | $421.97M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $12.81M | $444.37M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $19.54M | $280.28M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | $100.57M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | $123.53M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $337.63K | $1.61M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $91.07K | $1.91M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $300.45K | $147.80K | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $380.45K | $325.00K | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |